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ProteomicsThe master regulator of the adaptive response to hypoxia is HIF-1. However, while some data show that HIF-
1 can control more than 80% of the genes induced under hypoxia, other experiments clearly demonstrate
that a part of the hypoxic response is independent of HIF-1. The goal of this study was to identify some of
these HIF-1 independent factors and to investigate their functional role in the adaptation of tumor cells to
hypoxia. We show that the cytoplasmic dynein intermediate chain 2 (DH IC-2), a component of an
intracellular ATPase minus-end directed tubulin-based motile complex, was stabilized and post-
translationally modiﬁed under hypoxia in a HIF-1 independent way. We identiﬁed this modiﬁcation as a
phosphorylation by protein kinase C, which is inhibited under hypoxia. In parallel, the migration of HepG2
cells was enhanced under hypoxia. Cell migration was also increased, to the same extent, by the invalidation
of DH IC-2 using siRNA. Taken together, these results suggest that under hypoxia, a speciﬁc modiﬁcation of
DH IC-2 may modulate its activity, and in turn promote cell migration. These results are important to better
understand cancer development since they highlight a HIF-1 independent mechanism, which may be
involved in metastasis.
© 2009 Elsevier B.V. All rights reserved.1. Introduction
Oxidoreduction mechanisms are the most predominant way to
provide energy supply to mammalian cells, which in turn allow cell
survival and growth [1]. Hypoxia is characterized by a decrease in
oxygen availability, and cells have to adapt in order to survive to this
condition. Themaster regulator of this adaptive response to hypoxia is
HIF-1 [2,3]. This transcription factor is a member of the bHLH-PAS
family and is composed of two subunits: HIF-1α and ARNT (aryl
hydrocarbon receptor nuclear translocator) [4]. HIF-1α is the
regulatory subunit of HIF-1 and is subjected to proteosomal
degradation under normoxic conditions [5]. Under hypoxia, HIF-1α
is stabilized and translocates into the nucleus where it associates with
its constitutively expressed partner ARNT, which is also known to be
involved in xenobiotic detoxiﬁcation pathway [6]. HIF-1 can transac-
tivate a variety of genes involved in multiple pathways such as
glycolysis (enolase, aldolase, glucose transporter 1/3) [3], angiogen-
esis [VEGF (vascular endothelial growth factor), VEGF-receptor 1] [7],
cell survival (Mcl-1) [8] and invasion (stromal cell derived factor
1-alpha, matrix metalloproteinase 1) [9].
Within a tumor, hypoxia can occur at different states of its
development [10,11]. For example, when a tumor is growing, the cellsB-5000 Namur, Belgium. Tel.:
hiels).
ll rights reserved.close to the blood vessels are well oxygenated, but when the tumor
mass expends, some cells are rejected to its periphery and they
become being too far to receive oxygen by diffusion from adjacent
capillaries [12]. Tumor cells also become hypoxic in case of blood ﬂow
arrest caused by any vascular problem like blood clot, by shunt or
simply by the irregular blood ﬂow observed in the immature tumor
vascular system [13].
Hypoxic conditions are important in cancer resistance to thera-
peutic treatments and are often associated with a poor patient
prognosis [14]. This is due to a reduced accessibility of drugs to the
hypoxic regions [15], to multi-drug resistant channel overexpression
in hypoxic tumor cells [16] and to protection from cell death by
blockade of some apoptotic pathways [17].
Consequently, several strategies are now developed aimed to
invalidate the adaptive response of tumor cells to hypoxia [18]. Most
of these approaches target the HIF-1 pathway or the VEGF receptor,
and promising results have already been obtained [19]. However,
while some data showed that HIF-1 could control until 80% of the
genes induced under hypoxia [2], other experiments clearly demon-
strated that a part of the hypoxic response is independent of HIF-1
[20–23]. In that way, and as tumor cells are well known to raise a high
plasticity and to be able to escape from numerous regulatory
mechanisms, it is important to better understand the HIF-1 indepen-
dent actors of the adaptive response to hypoxia.
The goal of this study was to identify some of these HIF-1
independent factors and to investigate their functional role in the
adaptation of tumor cells to hypoxia. For this purpose, we used the
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model [8], exposed to the chemical compound CoCl2, a well-known
inducer of HIF-1 [24] or to true hypoxia.
In this report, we show that the cytoplasmic dynein intermediate
chain 2 (DH IC-2), a component of an intracellular ATPase minus-end
directed tubulin-based motile complex [25], was stabilized and post-
translationally modiﬁed under hypoxia, in a HIF-1 independent way.
DH IC-2 was phosphorylated by protein kinase C (PKC) under
normoxia and was found to be de-phosphorylated under hypoxia.
Dynein is a large multi-subunit protein principally composed of four
components: the heavy chain (530 kDa), the intermediate chain
(75 kDa), the light intermediate chain (30–50 kDa) and the light chain
(10–14 kDa) [26]. Dyneins are clustered in two groups: cytoplasmic
and axonemal [27]. Cytoplasmic dyneins are involved in intracellular
transport, mitosis, cell polarization and directed cell movement [28].
Axonemal dyneins are responsible for ciliary and ﬂagellar beating
[29]. We also showed that the migration of HepG2 cells was enhanced
under hypoxia and, to the same extent, by the invalidation of DH IC-2
using siRNA. These results suggest that under hypoxia, a speciﬁc
modiﬁcation of DH IC-2 may modulate its activity, and in turn
promote cell migration.
2. Materials and methods
2.1. Cell culture and stimulation
Murine hepatoma HepaC4 cells (kindly donated by Prof. Hankin-
son, UCLA)were cultured in Dulbecco's modiﬁed Eagle's medium high
glucose-4000 mg/l (DHG) (Gibco, Paisley, UK) supplemented with L-
glutamine (Sigma Aldrich, St. Louis, MO) containing 10% fetal calf
serum (Gibco, Paisley, UK) at 37 °C and 5% CO2. Cells were plated at
80% 1 day before the incubation under hypoxic or normoxic
conditions.
Human hepatoma HepG2 cells (ATCC) were grown in Dulbecco's
modiﬁed Eagle's medium low glucose-1000 mg/l (DMEM) (Gibco,
Paisley, UK) supplemented with L-glutamine (Sigma, St. Louis, MO)
containing 10% fetal calf serum (Gibco, Paisley, UK) at 37 °C and 5%
CO2. Cells were plated at 8 × 104 cells/cm2 1 day before the incubation
under hypoxic or normoxic conditions.
Hypoxia incubations were performed in serum-free CO2-indepen-
dent medium (Gibco, Paisley, UK) supplemented with 10 mM L-
glutamine (Sigma Aldrich, St. Louis, MO) under 99% N2 and 1% O2.
Control normoxic cells were maintained under normal atmosphere
(20% O2). The oxygen concentration in the medium obtained in our
experimental conditions is 10 mmHg.
Cycloheximide at 20 μM (CHX) (Sigma Aldrich, St. Louis, MO),
MG132 at 20 μM (Biomol/Tebu-Bio Boechout, Belgium), calphostin C
at 2 μM (El-198, Biomol/Tebu-Bio Boechout, Belgium), SB203580 at
20 μM (Alexis, Hausen, Switzerland), DRB at 100 μM (5,6-dichloro-1-
β-D-ribofuranosyl-benzimidazole, Biomol/Tebu-Bio Boechout, Bel-
gium), PMA at 0.3 μM (phorbol-12-myristat-13-acetate, Sigma
Aldrich, St. Louis, MO) and CoCl2 at 150 μM (Sigma Aldrich, St.
Louis, MO) incubations were performed in serum-free CO2-indepen-
dent medium (Gibco, Paisley, UK) supplemented with 10 mM L-
glutamine (Sigma Aldrich, St. Louis, MO). All supplemented media
were ﬁltered on 0.22 μm porous membrane.
2.2. 2D DIGE analyses
2.2.1. Sample preparation
After elimination of the medium, cells were collected in 1 ml of
pre-cooled PBS, transferred into microtubes and centrifuged 4 min at
1000 rpm at 4 °C. The pellets were lysed with the DIGE Labeling (DLA)
buffer (CHAPS 4%, urea 7 M, thiourea 2 M, Tris 30 mM, pH 8.5) and
clariﬁed by centrifugation at 13,000 rpm for 5 min at 4 °C.2.2.2. Protein labeling
Protein concentrations were determined in triplicates by the
Bradford method (Bio-Rad, München, Germany) and extracts were
diluted to reach a ﬁnal concentration of 5–10 μg/μl. The pH of the
samples was adjusted to 8.5. Each sample (25 μg) was minimally
labeled with the CyDyes DIGE (Amersham GE Healthcare, Uppsala,
Sweden) during 30 min in the dark (200 pmol of amine-reactive
cyanine dyes, Cy3 or Cy5) at 4 °C following the manufacturer's
instructions. An internal standard, obtained after pooling an equal
amount of the six different samples, was labeled with Cy2. Labeling
was stopped by incubating the mixture 10 min with 1 μl of 10 mM
lysine (Sigma Aldrich, St. Louis, MO). Each gel was then loaded with
25 μg of mixed labeled samples (normoxia and normoxia + CoCl2, or
normoxia and hypoxia) and 25 μg of the internal standard. The
different mixes of proteins were diluted twice (CHAPS 4%, urea 7 M,
thiourea 2 M, Tris 30 mM, DTT 30 mM, IPG buffer 4–7 (v/v) 1%)
(Amersham GE Healthcare, Uppsala, Sweden) and reduced 20 min in
the dark at room temperature before clariﬁcation by centrifugation at
13,000 rpm during 10 min.
2.2.3. Two-dimensional differential in-gel electrophoresis
The ﬁrst dimension was performed with Immobiline DryStrips
(IPG strip continuous pH 4–7 gradient 24 cm; Amersham GE
Healthcare, Uppsala, Sweden). IPG strips were rehydrated in an
Immobiline DryStrip reswelling tray (Amersham GE Healthcare,
Uppsala, Sweden) for 24 h at RT with 450 μl of rehydration buffer
(CHAPS 4%, urea 7 M, thiourea 2 M, Tris 30 mM, DTT 30 mM, IPG
buffer 4–7 (v/v) 0.5%) and covered with 2.5 ml DryStrip oil.
Samples were loaded in a cupule at the more acidic part of the IPG
strips. Isoelectric focusing (IEF) was run on an IPGphor isoelectric
focusing system (Amersham GE Healthcare, Uppsala, Sweden) with
the following parameters: 300 V for 3 h, gradient step of 1000 V for
8 h, gradient step of 8000 V for 3 h and 8000 V for 65,000 V/h at
20 °C with a maximum current setting of 50 μA/strip. IPG strips
were then washed with distillated water, and incubated subse-
quently for 15 min with an equilibration buffer [Tris–HCl 50 mM
(pH 8.8), urea 6 M, glycerol (v/v) 30%, SDS (w/v) 2%] supple-
mented with DTT 10 mg/ml or iodoacetamide 25 mg/ml,
respectively. The IPG strips were then washed with running buffer
[Tris–HCl 50 mM (pH 8.5), glycine 384 mM, SDS 0.2%] twice
concentrated and sealed with agarose 0.5% (containing bromophe-
nol blue) on the top of a 10% SDS–PAGE pre-poured between low
ﬂuorescent glass plates using an Ettan-DALT caster (Amersham GE
Healthcare, Uppsala, Sweden). Twice concentrated buffer and
normal running buffer were added at the top and the bottom of
the gels, respectively. Electrophoresis was performed overnight
(16 h) at 14 °C with 1 W/gel in the EttanDalt II system (Amersham
GE Healthcare, Uppsala, Sweden). The three gels from a same
experiment were run at the same time.
2.2.4. Image acquisition and statistical analysis
In order to observe cyanin-labeled proteins, gels were scanned in
ﬂuorescence with Typhoon 9400 imager (Amersham GE Healthcare,
Uppsala, Sweden) at a resolution of 100 μm. Cy2 images were
obtained from a 488 nm excitation laser coupled to a 520 nm emission
ﬁlter. Cy3 images were obtained from a 532 nm excitation laser
coupled to a 580 nm emission ﬁlter. Cy5 images were obtained from a
633 nm excitation laser coupled to a 670 nm emission ﬁlter. A total of
nine gel images was generated for each comparative experiment and
analyzed using DeCyder Differential Analysis Software v6.0 (Amer-
sham GE Healthcare, Uppsala, Sweden) for spot detection, matching,
quantitation and statistical analysis. First, a differential in-gel analysis
(DIA) was applied on each gel to eliminate gel-to-gel variance by
matching and normalizing every spot gel with the corresponding
internal standard. Second, a biological variation analysis (BVA)
software, using student's t test (pb0.05), was run to detect statistical
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groups. Depending on the experiment, spots of interest were deﬁned
as spots with at least 1.3- or 1.5-fold change in abundance after
normalization.
2.2.5. Sample recovering
A preparative 2D gel was performed with 300 μg of unlabeled
proteins obtained by pooling the same amount of proteins from the
six samples used for the analytical gels. The protocol remained
unchanged as for analytical gels except that the sample was loaded in
two times for the ﬁrst dimension in order to decrease protein
precipitation; for the second dimension, one of the low ﬂuorescent
glass plates was pre-treated with bind-silane (Amersham GE
Healthcare, Uppsala, Sweden). At the end, the plate without bind-
silane was removed and the gel was incubated in a ﬁxating solution
(ethanol 30%, acetic acid 10%) for 5 h. Gels were then washed three
times for 30minwith distilledwater before overnight protein staining
with 1 l of ethanol 20% supplementedwith 7 μl of 20mMRuthenium II
solution [Ruthenium II tris (bathophenantroline disulfonate)]. Gels
were then washed twice with distilled water (Milli-Q system,
Millipore, Bedford, MA) for 10 min. Gels were scanned with Typhoon
9400 imager (Amersham GE Healthcare, Uppsala, Sweden) using a
532 nm excitation laser coupled to a 610 nm emission ﬁlter. After
matching the preparative gel picture to the master analytical gel
image, spots of interest were localized on the preparative gel and
picked with an automated Ettan Spot Picker (Amersham GE
Healthcare, Uppsala, Sweden) following the manufacturer's instruc-
tions. Spots were transferred in a 96-well plates and kept frozen at
−20 °C until protein digestion.
2.2.6. Protein extraction and digestion
Gel fragments were washed twice with distilled water (Milli-Q
system, Millipore, Bedford, MA) and once with acetonitril (ACN) 100%
at 900 rpm and 21 °C for 10 min. Pellets were then dried at 56 °C,
reduced with DTT 10 mM (Sigma Aldrich, St. Louis, MO) in NH4HCO3
100 mM during 45 min at 900 rpm and 56 °C, before alkylation
through incubation in iodoacetamide 55 mM in NH4HCO3 100 mM
during 30 min in the dark. Gel fragments were washed with distilled
water (Milli-Q system, Millipore, Bedford, MA), twice with ACN 100%
for 5 min at 900 rpm, once with NH4HCO3 100 mM at 900 rpm for
5 min and once with ACN 100% at 900 rpm for 10 min. Pellets were
dried at 37 °C during 20 min. Proteins were ﬁrst digested on ice with
trypsin 12.5 ng/μl (Promega, Madison) in 50 mM NH4CO3 for 45 min,
and then overnight at 37 °C. Peptides were extracted with 10 μl acid
formic 5% and the collected supernatants were kept frozen at – 20 °C
until mass spectrometry analysis.
2.2.7. Protein identiﬁcation
Digested peptides were ﬁrst separated on a nano C18 column
(Atlatis, 75 μM, 150 mm, 3 μm NanoEase column; Waters, Milford)
and then identiﬁed by Nano-LC-QTOF-MSMS. The mass spectrum of
peptide fragments was obtained through the use of a CapLC in tandem
with a Q-time-of-ﬂight 2 (Q-TOF2) (Waters, Milford) coupled to the
MassLynx 4.0 software (Waters, Milford).
Some proteins were also identiﬁed on the basis of their “peptide
mass ﬁngerprint” obtained with a matrix-assisted laser desorption/
ionization MX (Maldi) (Waters, Milford). Peptide mass maps were
acquired in the reﬂectronmode with delayed extraction. Mass spectra
were internally calibrated with trypsin autolysis peaks.
Full-length proteins were identiﬁedwithMascot software (version
2.0) (Matrix Sciences, London, UK) by sequence homology research
against human or murine protein databases.
2.2.8. Western blot
After elimination of the medium, cells were collected in 1 ml of
pre-cooled PBS and transferred into microtubes. Microtubes werecentrifuged 4 min at 1000 rpm at 4 °C. Supernatants were removed
and pellets were lysed with the extraction buffer [Tris 80 mM, pH 7.5
(Merck, Darmstadt, Germany), KCl 300 mM (Merck, Darmstadt,
Germany), EDTA 2 mM (Merck, Darmstadt, Germany), Triton X-100
1% (v/v) (Sigma, St. Louis, MO), containing a protease inhibitor
mixture (≪Complete≫ from Roche Molecular Biochemicals, 1 tablet
in 2 ml H2O, added at a 1:25 dilution) and phosphatase inhibitors
(NaVO3 25 mM, PNPP 250 mM, β-glycerophosphate 250 mM and NaF
125 mM, at a 1:25 dilution)]. Microtubes were then centrifuged 4 min
at 13,000 rpm at 4 °C. Supernatants were collected and stored at−80
°C. Protein concentrations were determined according to the Bradford
method (Bio-Rad, München, Germany). Equal amounts of protein
(20–40 μg) were then separated by SDS–PAGE on 10% acrylamide gel
and transferred to a polyvinyldiene diﬂuoride membrane (Amersham
Biosciences, Uppsala, Sweden). Membranes were blocked with Tris
buffer saline supplemented with 0.1% (v/v) Tween and 2% (w/v)
dried milk (ECL detection kit, Amersham GE Healthcare, Uppsala,
Sweden), and probed with the following antibodies: anti-HIF-1α
antibodies (BD Transduction Laboratories; diluted 1:2000), secondary
antibody anti-mouse horseradish peroxidase-conjugated (Amersham
GE Healthcare, Uppsala, Sweden; diluted 1:300,000), anti-α-tubulin
antibodies (Sigma, St. Louis, MO; diluted 1:50,000), secondary
antibody anti-mouse horseradish peroxidase-conjugated (Amersham
GE Healthcare, Uppsala, Sweden; diluted 1:300,000), anti-DH IC-2
intermediate chain antibodies (Abcam #ab6304, clone 70.1; diluted
1:50,000), secondary antibody anti-mouse horseradish peroxidase-
conjugated (Amersham GE Healthcare, Uppsala, Sweden; diluted
1:300,000), anti-p53 antibodies (Upstate; diluted 1:5000), and
secondary antibody anti-mouse horseradish peroxidase-conjugated
(Amersham GE Healthcare, Uppsala, Sweden; diluted 1:300,000).
Proteins were detected by chemoluminescence (ECL detection kit,
Amersham GE Healthcare, Uppsala, Sweden) using a Fujiﬁlm FPM-
100A (Fujiﬁlm, Düsseldorf, Germany). Films were scanned with the
Image Master Labscan V2003.01 Software (Amersham GE Healthcare,
Uppsala, Sweden) and semi-quantitated with the ImageQuant
TotalLab V2,3.03 software (Amersham GE Healthcare, Uppsala,
Sweden).
2.2.9. 2D-blot
Cells were collected and lysed and 100 μg of each sample were
prepared as for 2D preparative gels. First dimension was performed
with Immobiline DryStrips (IPG strip continuous pH 4–7 gradient,
18 cm; Amersham GE Healthcare, Uppsala, Sweden) pre-rehydrated
during 24 h at RT with 350 μl of rehydration buffer (CHAPS 4%, urea
7 M, thiourea 2 M, Tris 30 mM, DTT 30 mM, IPG buffer 4–7 (v/v)
0.5%). Samples were loaded as for 2D gels, and ran with the following
parameters: 300 V for 3 h, gradient step of 1000 V for 8 h, gradient
step of 8000 V for 3 h and 8000 V for 25,000 V/h at 20 °C with a
maximum current setting of 50 μA/strip [IPGphor isoelectric focusing
system, Amersham GE Healthcare, Uppsala, Sweden]. IPG strips were
then washed, equilibrated and sealed with agarose 0.5% (containing
bromophenol blue) on the top of a 10% SDS–PAGE as for 2D gels.
After protein separation, samples were transferred to a polyvinyl-
diene diﬂuoride membrane (Amersham Biosciences, Uppsala, Swe-
den), blocked with phosphate saline buffer supplemented with 0.1%
(v/v) Tween and 2% (w/v) dried milk (ECL detection kit, Amersham
GE Healthcare, Uppsala, Sweden) and probed as described for
Western blot. The three gels of a same experiment were run at the
same time.
2.2.10. Immunoprecipitation
HepG2 cells were seeded at 80,000/cm2 in DMEM+ 10% FBS and
grown for 24 h before starting the experiments. After the incubation,
cells were lysed in 1 ml IP lysis buffer [25 mM Tris, pH 7.8, 100 mM
NaCl, 1 mM EDTA, 10% glycerol (Merck, Darmstadt, Germany), 0.2%
NP-40 (Sigma, St. Louis, MO), 1 mM DTT (Sigma, St. Louis, MO), 1 mM
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1 mM NaMoO4 (Sigma, St. Louis, MO) and 60 μM MG132 (Biomol/
Tebu-Bio Boechout, Belgium)]. An aliquot of 50 μl was kept for
assessing the protein level of DH IC-2 in the cell extracts. Lysates were
incubated 2 h at 4 °C with 2.5 μg of anti-DH IC-2 IgG, then 2 h at 4 °C
with 50 μl proteinA/G coated beads (BD bioscience). The beads were
washed three timeswith 800 μl of the IP lysis buffer, afterwhichDH IC-
2 was recovered by incubating the beads in Laemmli buffer for 10 min
at 100 °C. Sampleswere resolved on 10% SDS–PAGE and transferred on
polyvinyldiene diﬂuoride membrane. Proteins were detected with
anti-DH IC-2 or pan-serine/threonine speciﬁc IgG (#44-006, Upstate,
Lake Placid).
2.2.11. PKC kinase activity assay
HepG2 cells were seeded at 80,000/cm2 in DMEM + 10% FBS
and grown for 24 h before starting the experiments. After the
incubation, the medium was removed and replaced with 1 ml of
fresh lysis buffer [20 mM MOPS (Merck, Darmstadt, Germany),
50 mM α-glycerophosphate (Prolabo, Pennsylvania), 50 mM sodium
ﬂuoride (Merck, Darmstadt, Germany), 1 mM sodium vanadate
(Sigma), 5 mM EGTA (Sigma, St. Louis, MO), 2 mM EDTA (Merck,
Darmstadt, Germany), 1% (v/v) NP40 (Sigma, St. Louis, MO), 1 mM
dithiothreitol (DTT) (Sigma, St. Louis, MO), 1 mM benzamidine
(Sigma, St. Louis, MO), 1 mM phenylmethanesulphonylﬂuoride
(PMSF) (Sigma, St. Louis, MO) and protease inhibitors 4% (v/v)
(Complete®; Roche)] and was added per T25 ﬂask and the ﬂasks
were put on ice. After 10-min incubation period, cells were scraped
using a cell scraper and cell lysates were collected in a pre-chilled
1.5 ml microtube kept on ice. Microtubes were centrifuged at 13,000
× g for 15 min at 4 °C. Clear supernatant was transferred to a pre-
chilled 1.5 ml microtube and protein concentration was determined
using Bradford method. The assay was performed immediately after
cell lysis using a PKC Kinase Activity Assay Kit (Non-Radioactive)
(Assay Designs, Ann Arbor) with 20 μg of fresh lysate proteins for
each condition.
2.2.12. Total RNA extraction and reverse transcription
After the incubation, the medium was removed and total RNA
extraction was performed using RNAgents kit according to the
manufacturer's instructions (RNAgents, Total RNA Isolation System,
Promega, Madison). For each condition, 2 μg of total RNA were
mixed with 2 μl oligo (dT) (500 ng/μl) (Gibco, Paisley, UK). The
volume was then brought up to 9 μl with nuclease-free water
(Promega, Madison). This mix was ﬁrst incubated for 10 min at
70 °C and then on ice for 5 min. Reaction mix [9 μl; 4 μl Buffer RT 5X
(Promega, Madison), 2 μl DTT 0.1 M (Promega, Madison), 1 μl
RNAsin (40 U/μl) (Promega, Madison), 2 μl dNTP mix (Eurogentec,
Seraing, Belgium)] was added and the samples were left for 5 min at
room temperature. After addition of 1.5 μl SuperScriptRII (200 U/μl)
(Invitrogen, Carlsbad), the samples were incubated for 90 min at
42 °C and then for 15 min at 70 °C. Finally, 1 μl of Ribonuclease H (2
U/μl) (Gibco, Paisley, UK) was incubated with the samples for 20 min
at 37 °C before being stored at −20 °C. Sequences of the primers
were determined using Primer Express 1.5 software (Applied
Biosystems, Foster City): DH IC-2, 5′-AACACAAAATGCTCACAA-
TCTGATTAG-3′ (forward) and 5′-TGCTATCCTGTGGATGGGAAA-3′
(reverse); aldolase, 5′-TGCGCAGGAGGAGTATGTCA-3′ (forward)
and 5′-AGGCGTGGTTAGAGACGAAGAG-3′ (reverse); Rpl13, 5′-
GCCTACAAGAAAGTTTGCCTATCTG-3 ′ (forward) and 5 ′-
TGAGCTGTTTCTTCTTCCGGTAGT-3′ (reverse). cDNAs and primer
concentrations were experimentally determined to allow PCRs to
remain in the exponential zone of ampliﬁcation, and the speciﬁcity of
the PCR was checked by carrying out a dissociation curve with a
gradient from 60 °C to 95 °C. cDNAs (5 μl) were added to SYBR Green
Master Mix PCR [2.5 μl distilled water, 1.7 μl of reverse primer at
9 μM, 1.7 μl of forward primer at 9 μM, 12.5 μl of SYBR green] andPCRs were performed in 7900 HT Fast Real Time PCR System
(Applied Biosystems, The Netherlands) using SDS 2.2.1 Software
(Applied Biosystems, The Netherlands). Thermal cycling conditions
were as follows: 2 min at 50 °C, 10 min at 95 °C, 40 cycles of 30 s at
95 °C, 1 min at 57 °C and 30 s at 72 °C. Rpl13 ampliﬁcation was used
as a standard to normalized differences between samples, and fold
induction was estimated with the classical “ΔΔCT method” [30]. PCR
efﬁciency was higher than 90% for all genes.
2.2.13. Immunoﬂuorescence
HepG2 cells were seeded at 25,000/cm2 in DMEM + 10% FBS and
grown on glass cover slide for 24 h before starting the experiments.
After the incubation, the medium was removed, and cells were ﬁxed
for 10 min with PBS containing 4% (w/v) paraformaldehyde (Merck,
Darmstadt, Germany). Fixed cells were washed three times with PBS
and permeabilized with PBS–Triton X-100 1% (w/v) (Sigma, St.
Louis, MO) during 4 min. After three washing steps with PBS
containing 2% (w/v) bovine serum albumin (BSA) (PAA Laborato-
ries), cells were incubated during 2 h under wet atmosphere at
room temperature with anti-DH IC-2 intermediate chain antibodies
[Abcam #ab6304, clone 70.1; diluted 1:100 in PBS + 2% (w/v) BSA].
Cells were then washed three times with PBS + 2% (w/v) BSA, and
the secondary antibodies conjugated to Alexa ﬂuorochrome 488
[Molecular Probes; diluted 1:1000 in PBS + 2% (w/v) BSA] were
added under wet atmosphere at room temperature for 1 h. The cells
were then washed three times with PBS. Nuclei were labeled with
Topro-3 [Molecular Probes; diluted 1:80 in PBS + RNase 2 mg/ml
(ICN)] during 30 min. Finally, the cells were mounted in mowiol
(Sigma, St. Louis, MO). Observations were performed with a
confocal microscope using a constant photomultiplier (Leica, Groot
Bijgaarden, Belgium).
2.2.14. Cell viability assay
HepG2 cells were seeded at a density of 12×103/cm2 in DMEM+
10% FBS and grown on 24 h before starting the experiments. After the
incubation, cell viability was evaluated by 3-(4,5-dimethylthiazol-2-
yl)-2,5-diphenyltetrazolium bromide reduction assay (MTT) (Sigma,
St. Louis, MO) [31]. MTT solutionwas added volume-to-volume for 2 h
at 37 °C under 5% CO2, and then discarded before overnight incubation
in lysis buffer [20% SDS (MP Biomedicals, Eschwege, Germany), 33.3%
N,N-dimethyl-formamide (Merck, Darmstadt, Germany), pH 4.7]
under shaking (100 rpm) at 37 °C in the dark. The OD values were
recorded at 570 nm (plate reader Ultramark Microplate Imaging
System, Bio-Rad, München, Germany).
2.2.15. Migration assay
HepG2 cells were plated (100,000/300 μl/well) in Boyden
chambers, on the top of 8 μm pore polycarbonate membrane
(Transwell, Costar, Corning, NY) in serum-free CO2-independent
medium (Gibco, Paisley, UK) supplemented with 10 mM L-glutamine
(Sigma, St. Louis, MO). These chambers were maintained in 24-wells
plates and 600 μl/well of CO2-independent medium (Gibco, Paisley,
UK) supplemented with 10 mM L-glutamine (Sigma, St. Louis, MO)
and 10% FBS were placed at the bottom of wells as a chemotaxis
inducer. After 24-h incubation, the cells having migrated on the other
side of the porous membrane were stained with crystal violet [crystal
violet 4.8 mM (Janssen, Geel, Belgium), ethanol 2%] as follows:
Transwell inserts were ﬁrst washed three times in PBS, ﬁxed 45 s with
methanol pre-cooled to −20 °C, washed three times with distilled
water, incubated 45 s with crystal violet solution and washed three
times with distilled water. The top of the porousmembranes was then
cleaned of cells twice with a cotton swab, cut with a scalpel blade and
mounted with Glycergel (Dako, Denmark). Cover slides were
maintained under weight overnight at room temperature to avoid
air bubbles. Observations were performed with DIALUX 20EB
photonic microscope (Leica, Groot Bijgaarden, Belgium) coupled
Table 1
List of HIF-1 independent hypoxia-responsive proteins identiﬁed by mass spectrometry in HepaC4 cells.
Master
no.
Name T-test Av. Ratio pI Mw Pept. Protein ID Comment
340 p137GPI 0.0039 −1.54 4.96 78120 5 Q61620 Regulates the transport and translation of mRNAs of proteins
involved in synaptic plasticity in neurons and cell proliferation and
migration in multiple cell types.
374 Alanyl tRNA synthetase 0.046 1.56 5.18 106647 6 Q8BXR0 Transfers alanyl on tRNA.
488 Cortactin 0.011 1.57 5.07 61222 14 Q60598 Involved in organization of cell structure. May contribute to cellular
growth regulation and transformation.
488 Vasolin Containing Protein 0.011 1.57 4.95 89265 7 Q01853 Containing Protein Necessary for the fragmentation of Golgi stacks
during mitosis, for the export of misfolded proteins from the ER to
the cytoplasm. Regulates spindle disassembly.
516 Hypothetical Pyridoxal-Dependent
Decarboxylase Family Protein
0.0086 2.54 5.22 78493 4 Q3TN13 Decarboxylase Family Protein Decarboxylase.
546 Ribonucleotide Reductase M1 0.0017 2.06 6.15 90093 7 Q91YM8 Provides the precursors necessary for DNA synthesis. Catalyzes the
biosynthesis of deoxyribonucleotides from the corresponding
ribonucleotides.
567 Ribonucleotide Reductase M1 0.00071 −2.11 6.15 90093 4 Q91YM8 Provides the precursors necessary for DNA synthesis. Catalyzes the
biosynthesis of deoxyribonucleotides from the corresponding
ribonucleotides.
600 Mitochondrial elongation factor G1 0.00085 2.1 6.35 83614 2 Q921D6 Promotes the GTP-dependent translocation of the nascent protein
chain from the A-site to the P-site of the ribosome.
648 SUMO-activating enzyme subunit 2 0.048 −1.92 4.9 70524 14 Q3U9J5 Mediates ATP-dependent activation of SUMO proteins.
648 Dynein Cytoplasmic Intermediate
Chain 2
0.048 −1.92 4.99 68351 9 Q3TGH7-3 Helps dynein bind to dynactin.
648 Cortactin 0.048 −1.92 5.07 61222 4 Q60598 Involved in organization of cell structure. May contribute to cellular
growth regulation and transformation.
662 Dynein Cytoplasmic Intermediate
Chain 2
0.0096 1.96 4.99 68351 11 Q3TGH7-3 Helps dynein bind to dynactin.
787 Lamin A/C 0.0009 1.89 6.54 74164 27 Q3TIH0 Component of the nuclear lamina.
793 TRIO and F-actin Binding protein 0.00036 −1.92 5.88 66938 14 Q99KW3 May regulate actin cytoskeletal organization, cell spreading and cell
contraction by directly binding and stabilizing ﬁlamentous F-actin.
872 Phosphoglucomutase 2 0.01 −1.96 6.12 74164 8 Q9D0F9 Participates in both the breakdown and the synthesis of glucose.
887 Signal Transducing Adaptator
Protein (SH3 domain and
ITAM motif) 2
0.00051 2.28 4.76 57418 2 Q8C8Y4 Involved in intracellular signal transduction mediated by
cytokines and growth factors. Plays a role in signaling
leading to DNA synthesis and c-myc induction.
894 Lamin A/C 0.00059 −2.56 6.54 74164 15 Q3TIH0 Component of the nuclear lamina.
899 Lamin A/C 0.0016 −2.33 6.54 74164 23 Q3TIH0 Component of the nuclear lamina.
910 Lamin A/C 0.0068 1.5 6.54 74164 21 Q3TIH0 Component of the nuclear lamina.
920 Lamin A/C 0.0068 1.5 6.54 74164 32 Q3TIH0 Component of the nuclear lamina.
929 TCP-1 Epsilon 0.02 1.69 5.62 59585 13 Q3TIE0 Molecular chaperone. Known to play a role, in vitro, in the
folding of actin and tubulin.
937 Dihydrolipoamide Dehydrogenase 0.028 1.74 7.81 54238 2 Q3UWP7 Component of the glycine cleavage system as well as of the
alphaketoacid dehydrogenase complexes.
937 U3 snoRNP-associated protein 0.028 1.74 7.77 52074 1 Q8CFB7 Participates in the processing and modiﬁcation of
pre-ribosomal RNA.
1000 Vimentin 0.0029 1.78 4.86 53655 21 Q8CCH1 Class-III intermediate ﬁlaments.
1121 Aldehyde dehydrogenase 2 0.013 −1.67 6.01 48239 9 P47738 Converts retinaldehyde to retinoic acid.
1219 Cytokeratin 18 0.0044 1.68 5.04 47509 20 Q3TIX1 Plays a role in ﬁlament reorganization. Involved in the uptake of
thrombin-antithrombin complexes by hepatic cells.
1254 Vimentin 0.018 1.68 4.86 53655 3 Q8CCH1 Class-III intermediate ﬁlaments.
1852 Stathmin 0.0007 1.56 5.87 17205 2 P54227 Prevents assembly and promotes disassembly of microtubules.
1856 Keratin 0.000016 3.46 7.74 61359 1 Q6IFZ6 Intermediate ﬁlament.
HepaC4 cells were incubated 16 h under hypoxia or normoxia. Hypoxia-responsive HIF-1 independent proteins were selected and then identiﬁed bymass spectrometry using aNano-
LC-QTOF-MSMS coupled to the MassLynx 4.0 software. Full-length proteins were identiﬁed with Mascot software (version 2.0) by sequence homology research against murine
protein databases. T-test=Student's t test (pb0.05); Av. Ratio=biological variation in induction fold; pI=isoelectric point; Mw=molecular weight; Pept.=number of matching
peptides.
1680 S. Pyr dit Ruys et al. / Biochimica et Biophysica Acta 1793 (2009) 1676–1690with a DC100 camera (Leica, Groot Bijgaarden, Belgium), using
DC100PPC software. Pictures were taken at the same swelling,
contrast and luminosity.
2.2.16. siRNA transfection
In order to invalidate HIF-1α or DH IC-2 expression, siGENOME
SMARTpool siRNA reagents M-0044018-02 and M-012574-00 were,
respectively, ordered from Dharmacon (Erembodegem, Belgium).
Non-targeting oligoribonucleotides D-00120-01-20 (Dharmacon,
Erembodegem, Belgium) was used as negative control. One day
before transfection, HepG2 cells were plated at 40×103/cm2 andFig. 1. Representative proteomic maps (2D-gels). HepG2 cells were incubated 16 h unde
isoelectrically focused and then separated as described in Materials and methods. The arrogrown in DMEM + 10% FBS. Cells were transfected according to the
manufacturer's instructions (Dharmacon, Erembodegem, Belgium)
for 24 h with siRNA at 50 nM in DMEM medium using Dharmafect 1
transfection reagent. Cells were seeded 24 h after transfection for the
different assays.
2.2.17. In silico analysis tools
The in silico analysis tools are available online: http://www.cbs.
dtu.dk/services/NetPhos/, http://www.ba.itb.cnr.it/BIG/UTRScan/,
http://www.expasy.org/tools/ - ptm, http://www.matrixscience.
com/.r normoxia, normoxia + CoCl2 150 μM or hypoxia. Total cell extracts (75 μg) were
ws with numbers represent spots with identiﬁed proteins which are listed in Table 2.
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One way analysis of variance (ANOVA) with post-hoc pairwise
comparison using Holm–Sidak method was performed using Sigma-
Stat.3 software.
3. Results
3.1. 2D-DIGE analysis, experimental procedure and mass spectrometry
In order to identify HIF-1 independent proteins involved in the
adaptive response to hypoxia, we used the murine hepatoma cell line
HepaC4, which lacks ARNT, and hence, does not harbor a functional
HIF-1. Cells were ﬁrst incubated during 16 h under normoxia or
hypoxia. After lysis, proteins were labeled with different dyes to
perform 2D-DIGE approach and the gels were analyzed by the
DeCyder software [32]. We decided to focus on proteins that had their
relative abundance statistically modiﬁed at least by 50% under
hypoxia in comparison to normoxia (p=0.05).
A total of 21 hypoxia-responsive proteins were identiﬁed by mass
spectrometry (Table 1). Most of them were clustered into cytoskel-
eton or associated to cytoskeleton proteins (like vimentin, cortactin,
DH IC-2 and lamin). We then tried to conﬁrm these variations using
Western blot analyses. However, no correlation between the apparent
modiﬁcation of abundance observed in 2D-DIGE and the abundance of
the proteins was observed. Real-time PCR, to assay the mRNA level,
and immunoﬂuorescence, to evidence changes in abundance and in
subcellular localization, did not neither reveal any variation (data not
shown).
In order to circumvent this problem, we decided to use the same
kind of approach using a closely related human hepatoma cell line, the
HepG2 cells. We decided to compare the protein proﬁle of cells
incubated under hypoxia to the one of cells incubated in the presence
of CoCl2 under normoxia. Hypoxia allowed us to identify HIF-1
dependent and independent hypoxia-responsive proteins while CoCl2
only highlighted the HIF-1 dependent ones. We next removed the
common proteins of both experiments and generated a list of HIF-1
independent hypoxia-responsive proteins. To optimize our chances to
identify proteins common with the previous experiment, we focused
our attention on proteins that had their relative abundance changed
at least by 30% under hypoxia. Normoxia was used as the control.
First, to conﬁrm that HepG2 cells are responsive to CoCl2, we
checked the stabilization of HIF-1α under normoxia in the presence of
CoCl2 orunderhypoxia after 16h incubation (data not shown). Hypoxia
andCoCl2 did indeed lead to an increase inHIF-1αprotein level. Second,
we carried out 2D-DIGE approach where HepG2 cells were incubated
under normoxia, normoxia with CoCl2 or hypoxia for 16 h. Fig. 1
illustrates the protein spots resolved by two-dimensional electropho-
resis for the three experimental conditions used here. After comparison
of the hypoxic and CoCl2-induced protein proﬁles, common spots were
removed andwe generated a list of 77 spots responsive to hypoxia in a
HIF-1 independent manner. Out of these spots, 63 proteins were
identiﬁed by mass spectrometry and clustered into different groups:
cytoskeleton or cytoskeleton-associated proteins (like coronin-1B, F-
actin capping protein alpha-2 subunit and DH IC-2), proteins involved
in translation process (like elongation factor 2, HNRPK, HNRPC and
aconitase), stress proteins, kinases and so on (Table 2).
We decided to focus on cytoskeleton proteins for two major
reasons. First, some of themwere already identiﬁed in the preliminary
experiment using HepaC4, like cortactin and DH IC-2. Second, these
cytoskeleton proteins may be involved in the migration process,
which is known to be enhanced under hypoxic conditions [33].
3.2. Increase in DH IC-2 protein level under hypoxia
In order to check whether the abundance of the different
cytoskeleton proteins identiﬁed by mass spectrometry are indeedincreased under hypoxia, HepG2 cells were incubated 16 h under
hypoxia or normoxia. Then, cells were lysed and total cell extract
proteins were loaded onto 10% SDS–PAGE. The abundance of ﬁve
cytoskeleton proteins identiﬁed in the previous study was monitored
by Western blot. The protein level of DH IC-2 was found to be
increased under hypoxia as shown in Fig. 2A. The hypoxia-induced
increase in DH IC-2 abundance was also conﬁrmed by immunoﬂuo-
rescence (Fig. 2B), but no change in subcellular localization was
observed. A time curve was also performed and the results show that
DH IC-2 abundance began to increase already after 4 h of incubation
under hypoxic conditions (Fig. 2C). All these experiments were
performed at least three times (data not shown).
3.3. DH IC-2 mRNA level in HepG2 cells under hypoxia
To determine whether the DH IC-2 up-regulation observed under
hypoxia is dependent on a transcriptional regulation, DH IC-2 mRNA
level was quantitated by real-time PCR. HepG2 cells were incubated
under hypoxia or normoxia in the presence or not of CoCl2. Total
mRNA was extracted and retrotranscripted into cDNA. Fig. 3 shows
that neither hypoxia nor CoCl2 did change the mRNA level of DH IC-2.
On the other hand, both conditions did increase the mRNA level of
aldolase, a well-known HIF-1 target gene (Fig. 3). These results
indicate that it is probably not through enhanced transcription that
the protein level of DH IC-2 is increased under hypoxic conditions.
3.4. DH IC-2 stabilization under hypoxia
In order to discriminate between protein stabilization and
enhanced translation to explain the increased protein DH IC-2
expression under hypoxia, a time course analysis using cycloheximide
10 μM (CHX), a well-known inhibitor of mammalian cell translation
[34], was performed under normoxia or hypoxia. As shown in Fig. 4A,
when HepG2 cells were treated with CHX under hypoxia, the total
amount of DH IC-2 did not diminish regardless of the incubation
duration. There was rather an increase in DH IC-2 protein abundance.
However, under normoxia, the level of DH IC-2 slightly decreased
according to the duration of the time course experiment. These results
suggest that, under hypoxia, the pool of DH IC-2 was stabilized, and
this contributed to the accumulation of the protein. This effect may be
due to an inhibition of the DH IC-2 degradation pathway under
hypoxia. As proteasome is one of the major proteolytic systems of
mammalian cells [35], we checked whether it could be involved in DH
IC-2 degradation. To this aim, we used the proteasome inhibitor
MG132 [36] at 40 μMunder normoxia and the protein level of DH IC-2
wasmonitored byWestern blot. As shown in Fig. 4B, DH IC-2 level was
not modiﬁed under normoxia regardless of the incubating conditions,
suggesting that another degradation pathway may be involved in DH
IC-2 turn over. p53 was used as a positive control of proteasome
inhibition. Its abundance indeed increased in the presence of MG132
(Fig. 4B).
3.5. DH IC-2 post-translational modiﬁcation under hypoxia
Since changes in 2D gel spots may be due to changes in expression
but also in post-translational modiﬁcation, we checked if DH IC-2
would also be post-translationally modiﬁed under hypoxia. 2D-blot
analyses were performed on proteins from HepG2 cells incubated
under the three different conditions. As shown in Fig. 5, DH IC-2 was
detected as two distinct spots under normoxia and after the
incubation in the presence of CoCl2. However, under hypoxia, only
one spot remained. These results suggest that DH IC-2 is modiﬁed
under hypoxia. Similar results were obtained for other cytoskeleton
proteins like tubulin, cortactin and coronin-1B (data not shown). The
DH IC-2 shift observed by 2D-blot under hypoxia, from the more
acidic form to the less one, may correspond to a loss of negative
Table 2
List of HIF-1 independent hypoxia-responsive proteins identiﬁed by mass spectrometry in HepG2 cells.
Master no. Name T-test Av. Ratio pI Mw Pept. Protein ID Comment
302 Oxygen-regulated
protein precursor
0.0017 −1.6 4.97 111266 19 Q9Y4L1 Role in cytoprotective cellular mechanisms triggered by
oxygen deprivation and other stresses as a molecular
chaperone.
Participates in protein folding.
459 Kinectin variant 1 0.026 1.9 5.36 156178 5 Q86UP2 Involved in kinesin-driven vesicle motility.
556⁎ Ubiquitin-protein
ligase E1
0.018 2.86 8.77 21404 29 P51965 Mediates the selective degradation of short-lived and
abnormal proteins.
705 Elongation factor 2 0.0067 1.64 6.49 95277 6 P13639 Promotes the GTP-dependent translocation of the nascent
protein chain from the A-site to the P-site of the ribosome.
708 Elongation factor 2 0.00096 1.58 6.49 95277 4 P13639 Promotes the GTP-dependent translocation of the nascent
protein chain from the A-site to the P-site of the ribosome.
708 Aconitase 1 0.00096 1.58 6.22 98336 9 Q5VZA7 Cofactor, binds 4Fe-4S.
708 Molybdenum cofactor
sulfurase
0.00096 1.58 6.24 98067 2 Q96EN8 Sulfurates the molybdenum cofactor.
708 P1-CDC21 0.00096 1.58 6.27 96497 10 P33991 Involved in the control of DNA replication.
804 Cortactin isoform a 0.0019 2.53 5.07 61548 13 Q96H99 Involved in organization of cell structure. May contribute
to cellular growth regulation and transformation.
811 HSP90 beta 0.0037 1.92 4.77 83212 28 P08238 Molecular chaperone.
889 eIF-4b 3.40E-05 4.78 5.3 69183 1 P23588 Required for the binding of mRNA to ribosomes.
899 Dynein intermediate
chain 2C
0.0041 −3.99 5.08 71456 2 Q13409-3 Helps dynein bind to dynactin.
916 Dynein intermediate
chain 2C
7.30E-05 2.74 5.08 71456 10 Q13409-3 Helps dynein bind to dynactin.
942 Cytokeratin 10 0.00012 2.54 4.95 59482 5 Q14664 Intermediate ﬁlament.
942 Prothrombin precursor 0.00012 2.54 5.52 69992 3 P00734 Cleaves bonds after Arg and Lys. Involved in blood
homeostasis, inﬂammation and wound healing.
942 Aglucosidase alpha 0.00012 2.54 5.56 10527 4 Q09GN4 Essential for the degradation of glygogen to glucose in
lysosomes.
1046 alpha tubulin 0.00078 1.64 5.76 49895 2 Q9BQE3 Component of microtubules.
1056 Dihydrolipoamide
acetyltransferase
8.00E-05 −1.96 5.97 65674 3 Q16783 Part of the pyruvate dehydrogenase complex, which
catalyzes the overall conversion of pyruvate to acetyl-CoA
and CO2.
1056 alpha-fetoprotein
precursor
8.00E-05 −1.96 5.3 68633 3 P02771 Binds copper, nickel, fatty acids and bilirubin less than
serum albumin.
1071 Serum albumin 0.00035 −2.77 6.09 69348 3 P02768 Main protein of plasma, has a good binding capacity for
water, Ca(2+), Na(+), K(+), fatty acids, hormones,
bilirubin and drugs. Involved in the regulation of the
colloidal osmotic pressure of blood.
1076 Lamin B1 0.013 −1.55 4.91 66367 19 P20700 Component of the nuclear lamina.
1121 Coronin 1B 0.00089 1.41 5.5 54200 5 Q9BR76 Regulates leading edge dynamics and cell motility in
ﬁbroblasts. May be involved in cytokinesis and signal
transduction.
1121 Ras-GTPase activating
protein binding protein 1
0.00089 1.41 5.2 52132 1 Q13283 May be a regulated effector of stress granule assembly.
1149 Dihydropyrimidinase-like 2 0.027 1.34 5.92 62254 6 Q53ET2 Involved in the metabolism of cyclic imides.
1175 HNRPK 0.012 −1.99 5.22 50944 13 Q07244 Pre-mRNA-binding proteins.
1175 Cytokeratin 9 0.012 −1.99 5.01 62091 6 Q14665 Plays a role in keratin ﬁlament assembly.
1175 TRAP1 0.012 −1.99 8.2 80059 1 Q12931 Chaperone.
1176 ERO1-L alpha 0.002 1.38 5.35 54358 2 Q96HE7 Oxidizes proteins in the endoplasmic reticulum to produce
disulﬁde bonds.
1176 Myo-inositol 1-phosphate
synthase 1
0.002 1.38 5.4 61029 5 Q9NPH2 Involved in myo-inositol biosynthesis pathway that
catalyzes the conversion of glucose 6-phosphate to
1-myo-inositol 1-phosphate in a NAD-dependent
manner.
1176 Copine-1 0.002 1.38 5.52 59058 9 Q99829 May function in membrane trafﬁcking.
1178 Lamin A/C 0.0063 1.35 6.58 74070 8 Q5I6Y4 Component of the nuclear lamina.
1192 HNRPK 0.021 1.58 5.22 50944 7 Q07244 Pre-mRNA-binding proteins.
1218 p21-activated
kinase 2
0.00026 1.45 5.59 57967 4 Q13177 Phosphorylates ribosomal protein S6, histone H4 and
myelin basic protein. Full-length PAK 2 stimulates cell
survival and cell growth.
1276 PDI 0.037 1.85 4.56 57080 6 Q15205 Catalyzes the formation, breakage and rearrangement of
disulﬁde bonds. Also acts a structural subunit of various
enzymes such as prolyl 4-hydroxylase and microsomal
triacylglycerol transfer protein MTTP.
1277 alpha tubulin 0.0091 1.57 5.76 49895 10 Q9BQE3 Component of microtubules.
1277 PDI 0.0091 1.57 4.57 57081 10 Q15205 Catalyzes the formation, breakage and rearrangement of
disulﬁde bonds. Also acts a structural subunit of various
enzymes such as prolyl 4-hydroxylase and microsomal
triacylglycerol transfer protein MTTP.
1289⁎ alpha tubulin 0.013 1.59 5.76 49895 15 Q9BQE3 Component of microtubules.
1296 DEAD box protein 19A 0.012 1.59 6.16 53940 7 Q9NUU7 ATP-dependent RNA helicase involved in mRNA export
from the nucleus.
1296 Glycerokinase 0.012 1.59 5.89 57542 6 Q8IVR5 Key enzyme in the regulation of glycerol uptake and
metabolism.
(continued on next page)
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Table 2 (continued)
Master no. Name T-test Av. Ratio pI Mw Pept. Protein ID Comment
1299 beta 2 tubulin 0.024 1.75 4.6 49799 19 P68371 Component of microtubules.
1299 MAPK7 transcript
variant 5
0.024 1.75 6.7 50360 1 Q59F50 Splice variant of ERK5. Lacks the NLS sequence and the
prolinerich domain.
1306 alpha tubulin 0.044 1.31 5.76 49895 12 Q9BQE3 Component of microtubules.
1312 beta 1 tubulin 0.034 1.35 5.76 49895 1 Q9BQE3 Component of microtubules.
1342 FKBP4 0.0015 −1.64 5.18 51772 4 Q02790 Component of unactivated mammalian steroid receptor
complexes that sediment at 8-10 S. May have a rotamase
activity. May play a role in the intracellular trafﬁcking of
hetero-oligomeric forms of steroid hormone receptors.
1346 beta 2 tubulin 0.0052 1.38 4.6 49799 24 P68371 Component of microtubules.
1357 beta 5 tubulin 0.049 1.86 4.55 49726 13 P07437 Component of microtubules.
1378 beta tubulin 0.0032 1.46 4.5 47736 16 Q5JP53 Component of microtubules.
1391 Heterogeneous nuclear
ribonucleoprotein H1
0.0097 1.34 5.85 49198 5 P31943 Component of the heterogeneous nuclear
ribonucleoprotein (hnRNP) complexes which provide the
substrate for the processing events that pre-mRNAs
undergo before becoming functional, translatable mRNAs
in the cytoplasm.
1402 alpha tubulin 0.00069 −7.19 5.76 49895 4 Q9BQE3 Component of microtubules.
1402 Cytokeratin 8 0.00069 −7.19 5.52 53704 20 Q14099 Helps to link the contractile apparatus to dystrophin at the
costameres of striated muscle.
1402 beta 5 tubulin 0.00069 −7.19 4.55 49726 2 P07437 Component of microtubules.
1414 Cytokeratin 8 0.0011 −2.88 5.52 53704 19 Q14099 Helps to link the contractile apparatus to dystrophin at the
costameres of striated muscle.
1445 Cytokeratin 10 0.014 1.44 5.13 59510 2 Q14664 Intermediate ﬁlament.
1445 alpha tubulin 0.014 1.44 5.76 49895 3 Q9BQE3 Component of microtubules.
1451 CSTF 50 0.0012 1.39 6.115 48326 8 Q05048 Required for polyadenylation and 3′-end cleavage of
mammalian pre-mRNAs. May be responsible for the
interaction of CSTF with other factors to form a stable
complex on the pre-mRNA.
1457 Rho GTPase activating
protein 1
0.048 1.34 5.82 50404 4 Q07960 GTPase activator for the Rho, Rac and Cdc42 proteins,
converting them to the putatively inactive GDP-bound state.
1471 DNA polymerase delta
subunit 2
0.041 1.69 5.21 51257 2 P49005 The function of the small subunit is not yet clear.
1483 Proteasome 26 s non
ATPase subunit 5
0.00088 1.59 5.3 56559 5 Q16401 Belongs to the 26S multi-subunit protease, which is
required for ubiquitin-dependent proteolysis.
1640 MAPKK2 0.0014 2.29 6.09 44396 4 P36507 Catalyzes the concomitant phosphorylation of a threonine
and a tyrosine residue in a Thr-Glu-Tyr sequence located in
MAP kinases. Activates the ERK1 and ERK2 MAP kinases.
1767 HNRPA/B 0.0029 −2.02 9.5 31327 2 Q99729 Binds single-stranded RNA.
1775 HNRPC 0.00012 3.16 4.8 32373 3 Q53EX2 Binds pre-mRNA and nucleates the assembly of 40S hnRNP
particles. Interacts with poly-U tracts in the 3′-UTR or 5′-
UTR of mRNA and modulates the stability and the level of
translation of bound mRNA molecules.
1802 HNRPC 9.30E-05 3.34 4.8 32373 2 Q53EX2 Binds pre-mRNA and nucleates the assembly of 40S hnRNP
particles. Interacts with poly-U tracts in the 3′-UTR or 5′-
UTR of mRNA and modulates the stability and the level of
translation of bound mRNA molecules
1848 eIF-2a 0.00033 1.44 4.82 36089 3 P05198 Functions in the early steps of protein synthesis by forming
a ternary complex with GTP and initiator tRNA.
1904 F-actin capping protein
alpha-2 subunit
0.013 1.5 5.47 32928 3 P47755 Binds in a Ca(2+)-independent manner to the fast
growing ends of actin ﬁlaments (barbed end) thereby
blocking the exchange of subunits at these ends.
1914 RPLPO 0.00072 2.72 8.43 27281 6 Q6NSF2 Component of the ribosome complex.
1926 SGTA 0.00035 2.04 4.59 34041 10 Q9BTZ9 Co-chaperone that binds directly to HSC70 and HSP70 and
regulates their ATPase activity.
1926 Nucleophosmin 0.00035 2.04 4.47 32439 2 Q12826 Associated with nucleolar ribonucleoprotein structures
and bind single-stranded nucleic acids. May function in the
assembly and/or transport of ribosome.
1931 SULT1A3 0.01 1.48 5.6 34174 1 Q6ZWJ5 Catalyzes the sulfate conjugation of phenolic monoamines
(neurotransmitters such as dopamine, norepinephrine and
serotonin) and phenolic and catechol drugs.
2042 Proteasome inhibitor
PI31 subunit
0.0007 1.3 5.32 29753 2 Q92530 Plays an important role in control of proteasome function.
Inhibits the hydrolysis of protein and peptide substrates by
the 20S proteasome.
2042 Copper chaperone for
superoxide dismutase
0.0007 1.3 5.02 29022 4 Q2M366 Delivers copper to copper zinc superoxide dismutase
(SOD1).
2129 RanBP1 0.0068 1.37 5.02 23295 1 P43487 Inhibits GTP exchange on Ran. Forms a Ran-GTP-RANBP1
trimeric complex. Increases GTP hydrolysis induced by the
Ran GTPase activating protein RANGAP1. May act in an
intracellular signaling pathway which may control the
progression through the cell cycle by regulating the
transport of protein and nucleic acids across the nuclear
membrane.
2137 Guanidinoacetate
N-methyltransferase
0.013 1.38 5.7 26301 3 Q14353 Involved in amine, polyamine and creatine biosynthesis.
2190 ITPA 0.011 1.36 5.35 21431 3 Q9BY32 May be the major enzyme responsible for regulating ITP
concentration in cells.
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Master no. Name T-test Av. Ratio pI Mw Pept. Protein ID Comment
2203 Catechol O-methyl
transferase
0.00026 1.57 5.11 30017 3 Q6IB07 Catalyzes the O-methylation, and thereby the inactivation
of catecholamine neurotransmitters and catechol
hormones.
2206 UMP-CMP kinase 0.00049 1.36 5.26 22208 6 Q53GB7 Catalyzes speciﬁc phosphoryl transfer from ATP to UMP
and CMP.
2212 Lysophospholipase 1 0.028 1.59 6.31 24653 4 Q9UQF9 Hydrolyzes fatty acids from S-acylated cysteine residues in
proteins such as trimeric G alpha proteins or HRAS. Has
also a low lysophospholipase activity.
2212 BAG-2 (BCL2-associated
athanogene 2)
0.028 1.59 6.25 23757 3 Q08AS9 Inhibits the chaperone activity of HSP70/HSC70 by
promoting substrate release.
2246 Adenine
phosphoribosyltransferase
0.014 1.32 5.65 19595 2 Q3KP55 Catalyzes a salvage reaction resulting in the formation of
AMP, that is energically less costly than de novo synthesis.
HepG2 cells were incubated 16 h under hypoxia or normoxia and CoCl2. Normoxia was used as the control. Hypoxia-responsive HIF-1 independent proteins were selected and then
identiﬁed by mass spectrometry using a Nano-LC-QTOF-MSMS coupled to the MassLynx 4.0 software. Full-length proteins were identiﬁed with Mascot software (version 2.0) by
sequence homology research against human protein databases. T-test=Student's t test (pb0.05); Av. Ratio=biological variation in induction fold; pI=isoelectric point;
Mw=molecular weight; Pept.=numbers of matching peptides. ⁎=protein identiﬁed by MALDI coupled to the MassLynx 4.0 software. Full-length proteins were also identiﬁed
with Mascot software (version 2.0) by sequence homology research against human protein databases.
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phosphorylation or of acetylation of this protein under hypoxia. In
silico research pointed out several potential phosphorylation sites in
the DH IC-2 protein sequence (data not shown). The intensity of the
spot detected under hypoxia by 2D-blot analysis should be more than
the sum of the two spots detected under normoxia. It is however
possible that the afﬁnity of the antibody for the unphosphorylated
form would not be the same as its afﬁnity for the phosphorylated
form, that would explain our results.
In order to conﬁrm that the change in the phosphorylation state of
DH IC-2 was independent of HIF-1, HIF-1α was invalidated using
siRNA. Fig. 6 shows that while HIF-1α protein abundance was
markedly decreased, HIF-1α invalidation did not inﬂuence the effect
of hypoxia on the modiﬁcation of DH IC-2 observed on 2D-blot.Fig. 2. Effect of hypoxia on DH IC-2 abundance and subcellular localization. (A) HepG2
cells were incubated 16 h under normoxia, normoxia + CoCl2 150 μM or hypoxia. Total
cell lysates were run on SDS–PAGE (10%) and probed with anti-DH IC-2 speciﬁc IgG.
α-Tubulin was used as loading control. (B) After incubation, cells were ﬁxed,
permeabilized and labeled with anti-DH IC-2 speciﬁc IgG. Observations were made
using a confocal microscope with a constant photomultiplier. (C) HepG2 cells were
incubated increasing time under normoxia or hypoxia. Total cell lysates were run on
SDS–PAGE (10%) and probed with anti-DH IC-2 speciﬁc IgG. p38 was used as loading
control.In order to identify the putative kinase responsible for the
phosphorylation of DH IC-2 under normoxia, we performed immu-
noprecipitation studies. Cells were ﬁrst treated with inhibitors of
different kinases (calphostin C for PKC, DRB for CK2 and SB203580 for
p38) under normoxic conditions or incubated in the presence of CoCl2
or under hypoxia and were then lysed. DH IC-2 was immunopreci-
pitated from the lysates, run onto a SDS–PAGE gel and revealed with
an anti-phosphorylated pan-serine-threonine antibody. The results
show that DH IC-2 was indeed phosphorylated under normoxic
conditions, CoCl2 did not inﬂuence it while hypoxia strongly inhibited
this phosphorylation (Fig. 7A). Moreover, under normoxia, the
phosphorylation was inhibited in the presence of calphostin C, a
PKC inhibitor, but not when CK2, p38 (Fig. 7A) or ERK (data not
shown) was inhibited. In order to conﬁrm these results, 2D-blot
analyses were performed on proteins from HepG2 cells incubated
under normoxia with or without calphostin C. As shown in Fig. 7B,
calphostin C markedly decreased the abundance of the more acidic
spot while in parallel it increased the abundance of the less acidic one,
which is similar to what was observed under hypoxia (see Fig. 5). All
together, these results suggest that DH IC-2 is phosphorylated by PKC
under normoxia and that hypoxia inhibited this post-translational
modiﬁcation.
In order to support this hypothesis, actual PKC activity was
assayed. Results from Fig. 7C show that hypoxia signiﬁcantly
decreased PKC activity, while CoCl2 had no effect. PMA, used as a
positive control, strongly increased PKC activity. It must be noted thatFig. 3. Effect of hypoxia on DH IC-2 and aldolase mRNA level. HepG2 cells were
incubated 16 h under normoxia, normoxia + CoCl2 150 μM or hypoxia. After
incubation, total RNA was extracted, retrotranscribed into cDNA and submitted to real-
time PCR for DH IC-2 and aldolase. Rpl13 was used as housekeeping gene. The results
are expressed in induction fold for three independent experiments, as means±SD
(n=3). ⁎⁎ or ⁎⁎⁎ pb0.01 or pb0.001 vs. normoxia.
Fig. 4. DH IC-2 stabilization under hypoxia. (A) HepG2 cells were incubated under
normoxia or hypoxia in a time course experiment in the presence of cycloheximide
10 μM (CHX). Total cell lysates (40 μg) were run on SDS–PAGE (10%) and probed with
anti-DH IC-2 speciﬁc IgG. The abundance of DH IC-2 was quantiﬁed and plotted. (B)
Effect of proteasome inhibition on DH IC-2 protein level. HepG2 cells were incubated
under normoxia in the presence or absence of MG132 (40 μM) during 16 h. Total cell
lysates (40 μg) were run on SDS–PAGE (10%) and probed with anti-DH IC-2 speciﬁc IgG.
p53 was used to monitor proteasome inhibition and α-tubulin was used as loading
control. Fig. 6. Effect of HIF-1α invalidation on DH IC-2 hypoxia-induced modiﬁcation. (A)
HepG2 cells were transfected with HIF-1α-directed siRNA for 24 h (NT=non-
transfected, Scr=non-targeting siRNA, HIF-1α siRNA=HIF-1α siRNA smartpool).
HepG2 cells were re-plated 24 h post-transfection and, 1 day later, incubated 8 h under
normoxia and hypoxia. Each sample (40 μg) was run on SDS–PAGE (10%) and probed
with anti-HIF-1α speciﬁc IgG. (B) HepG2 cells were ﬁrst transfected with HIF-1α-
directed siRNA for 24 h. After, HepG2 cells were re-plated 24 h post-transfection and, 1
day later, incubated 24 h under hypoxia. In parallel, non-transfected HepG2 cells were
incubated 16 h under normoxia or hypoxia. After incubation, 100 μg of each total cell
lysate were loaded on 18 cm IEF pH 4–7 strip. After the ﬁrst dimension, proteins were
separated on 10% SDS–PAGE and transferred on polyvinyldiene diﬂuoride membrane.
Proteins were detected with anti-DH IC-2 speciﬁc IgG.
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because it interfered with the measure of the optical density. These
data suggest that hypoxia may inhibit PKC activity after 16 h of
incubation.
3.6. DH IC-2 and migration
As DH IC-2 and other cytoskeleton proteins are modiﬁed under
hypoxia, we decided to investigate the possibility that these
modiﬁcations may affect cellular migration. For this purpose, DH IC-
2was invalidated in HepG2 cells by the use of siRNA. As a ﬁrst step, we
checked, in a time course experiment, that expression of DH IC-2 was
knocked-down after cell transfection in the presence of the siRNA. As
shown in Fig. 8, total invalidation of DH IC-2 was achieved 24 h post-
transfection and remained stable at least until 72 h post-transfection.Fig. 5. Post-translational modiﬁcation of DH IC-2 under hypoxia. HepG2 cells were
incubated 16 h under normoxia, normoxia+ CoCl2 150 μMor hypoxia. After incubation,
100 μg of total cell lysates were loaded on 18 cm IEF pH 4–7 strip. After the ﬁrst
dimension, proteins were separated on 10% SDS–PAGE and transferred on polyvinyl-
diene diﬂuoride membrane. Proteins were detected with anti-DH IC-2 speciﬁc IgG.We decided to perform the experiments between 24 and 48 h post-
transfection, according to the type of the assay. In order to observe the
impact of DH IC-2 invalidation on cell migration, transfected HepG2
cells were seeded on the top of porous membrane of Boyden-like
chambers. The chambers were then incubated either under normoxia
or hypoxia for 24 h. As shown in Fig. 9, HepG2 cells showed a higher
migration when incubated under hypoxia. This result is in accordance
with different in vitro and in vivo data from the literature, which show
an increase in metastatic potential in hypoxic cancers [9,37]. We also
observed, that under normoxia, HepG2 cells transfected with DH IC-2
targeting siRNA had a much more potent capacity to migrate through
the porous membrane than control cells. Under hypoxia, this
difference was attenuated. Under hypoxia, the total abundance of
DH IC-2 is increased and the protein is no longer phosphorylated. In
these conditions, HepG2 migration is enhanced. Two hypotheses can
thus be put forward: (i) it is the abundance of DH IC-2 that regulates
migration or (ii) that is the fact that DH IC-2 is phosphorylated or not.
Since when DH IC-2 expression is lowered (by the use of siRNA),
migration is also enhanced, we concluded that it is not its abundance
that regulates migration (otherwise we should have observed an
inhibition). We thus proposed that the phosphorylated form inhibits
migration, while the unphosphorylated one favors migration: hyp-
oxia, by inhibiting PKC activity and, hence, DH IC-2 phosphorylation
would thus enhance cell migration. In order to conﬁrm this
hypothesis, we used calphostin C, a speciﬁc PKC inhibitor: under
normoxia, PKC inhibition also resulted in an enhanced migration as
hypoxia did (Fig. 10A and B). The effect of calphostin C was similar to
the one of hypoxia, i.e., an increase in cell migration but the extent of
the effect was lower. This may be due to the fact that migration may
be regulated by several pathways under hypoxia, one of them being
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inhibited. In conclusion, hypoxia enhances migration at least in part
by inhibiting DH IC-2 phosphorylation. These results suggest that DH
IC-2 may be implicated in regulating the migration process, with a
negative impact on migration in well-oxygenated conditions.Fig. 7. Inhibition of DH IC-2 phosphorylation under hypoxia. (A) HepG2 cells were
incubated 16 h under normoxia, normoxia + CoCl2 150 μM, normoxia + calphostin C
2 μM, normoxia + DRB 100 μM, normoxia + SB203580 20 μM or hypoxia. After DH IC-2
immunoprecipitation, an equal part of the puriﬁed lysates was run on separate SDS–
PAGE (10%) and probed with anti-DH IC-2 speciﬁc IgG (i) or pan-anti-serine/threonine
IgG (ii). The abundance of the phosphorylated form of DH IC-2 has been quantiﬁed and
plotted (iii). (B) HepG2 cells were incubated 16 h under normoxia or normoxia +
calphostin C 2 μM. After incubation, 100 μg of total cell lysates were loaded on 18 cm IEF
pH 4–7 strip. After the ﬁrst dimension, proteins were separated on 10% SDS–PAGE and
transferred on polyvinyldiene diﬂuoride membrane. Proteins were detected with anti-
DH IC-2 speciﬁc IgG. (C) HepG2 cells were incubated 16 h under normoxia, normoxia +
CoCl2 150 μM or hypoxia. A positive control using PMA stimulation at 0.3 μM for 7 min
was also performed. After incubation, 20 μg of total cell lysates were used in ELISA to
monitor pan-PKC activity. Optical density was measured at 495 nm. Results are
presented as means±SD (n=3). ⁎ or ⁎⁎⁎, pb0.05 or pb0.001 vs. normoxia.
Fig. 8. Effect of DH IC-2-directed siRNA transfection on DH IC-2 protein level. HepG2
cells were transfected with DH IC-2-directed siRNA for 24 h (NT=non-transfected,
DF=Dharmafect 1 transfection agent, Scr=non-targeting siRNA, DH IC-2=DH IC-2
siRNA smartpool). Total cell lysates were collected 24, 48 or 72 h post-transfection. Each
sample (40 μg) was run on SDS–PAGE (10%) and probed with anti-DH IC-2 speciﬁc IgG.
α-Tubulin was used as loading control.In parallel with the migration experiments, transfected HepG2
cells were seeded to perform proliferation assays, and incubated
under normoxia or hypoxia during 24 h. Cell density was estimated by
the MTT method. As shown in Fig. 11, invalidation of DH IC-2 did not
change HepG2 cell proliferation rate. Taken together, these results
showed that cell migration is enhanced by hypoxia and, to the same
extent, by DH IC-2 invalidation in a ce:paraproliferation-independent
way.
4. Discussion
Cancer represents one of the major causes of mortality in
developed countries. Today, tumor hypoxia is a hot spot in cancer
research and its impact on cancer development and patient outcome
is well described. As hypoxia is more often correlated with a poor
prognosis for the patient [38], adaptive responses to hypoxia are
intensively investigated. HIF-1 controls the majority of the genes
induced by hypoxia [2] and most of the studies that try to impair
cancer cell adaptation to hypoxia are focused on the HIF pathway [19].
However, some data clearly show that other factors may also
participate to this adaptation, through a transcriptional effect or in
other ways like protein interaction or post-translational modiﬁcation
[20–23]. Indeed, overexpression of a constitutive active form of HIF-1
does not recapitulate all the genes induced by hypoxia [20], and the
invalidation of HIF-1 does not suppress the apoptosis protection
observed under hypoxia, indicating that HIF-1 independent processes
are involved [21]. In order to investigate these processes, we decided
to identify proteins that participate to cellular adaptation to hypoxia
in a HIF-1 independent way. We used the murine cell line HepaC4,
which lacks the ARNT subunit of HIF-1 [39]. In that way, HepaC4 cells
do not have a functional HIF-1 and can not transactivate HIF-1 target
genes [40]. 2D-DIGE analyses were performed in order to identify
hypoxia-responsive HIF-1 independent proteins, but no correlation
was observed between the apparent overexpression pointed out in
these analytical analyses and the mRNA or protein level of the
putative candidates. These discrepancies between 2D-DIGE, real-time
PCR and Western blot results are probably due to the fact that 2D-
DIGE highlights post-translational modiﬁcations in addition to
changes in overall expression. In order to increase the probability to
identify some hypoxia-responsive HIF-1 independent proteins, new
2D-DIGE experiments using CoCl2, a well-known inducer of HIF-1
[24], were carried out, using the human hepatoma cell line HepG2.
These cells are sensitive to CoCl2 and represent a well-established
hypoxia model [8].
It is known that CoCl2 may also affect other cellular functions than
the HIF-1 pathway [41], but as we removed the results generated by
this approach from the ones obtained with hypoxia, we did not
increase the rate of false positives. However, it is possible that we
excluded some hypoxia HIF-1 independent spots, due to a side effect
of this molecule in a HIF-1 independent hypoxia-responsive pathway,
Fig. 9. Effect of DH IC-2 invalidation on HepG2 migration. HepG2 cells were transfected
with DH IC-2-directed siRNA for 24 h (NT=non-transfected, DF=Dharmafect 1
transfection agent, Scr=non-targeting siRNA, DH IC-2 siRNA=DH IC-2 siRNA smart-
pool). HepG2 cells were re-plated in Boyden-like chambers 24 h post-transfection and
incubated 24 h under normoxia and hypoxia. (A) Cells that have migrated were stained
with crystal violet. (B) The actual number of cells that have migrated has been counted
on three ﬁelds for each membrane of each experiment. The results are expressed in
induction fold for three independent experiments, as means±SD (n=3). ⁎⁎⁎, pb0.001
vs. normoxia; (⁎⁎⁎), pb0.001 vs. hypoxia.
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the lists of the different proteins identiﬁed by mass spectrometry in
both experiments, we decided to focus on some cytoskeleton proteins
for two major reasons. First, they were already identiﬁed in the
previous experiments using the two murine cell lines. Second, they
may be involved in regulating the migration process, which is known
to be enhanced under hypoxic conditions. Out of these proteins, only
the abundance of DH IC-2 was increased at the protein level. As DH IC-
2 is a component of cytoplasmic dynein, which is involved in directedcell movement [42], we decided to focus on this protein. We ﬁrst
investigated if the increase in DH IC-2 protein level was dependent on
a transcriptional effect. As DH IC-2 mRNA level was not elevated
under hypoxia, we next investigated if the increase in DH IC-2 protein
level may be the consequence of a stabilization of the protein.
Blockage of protein synthesis by cycloheximide and follow-up of DH
IC-2 protein level in a time course experiment revealed that this
protein is less degraded under hypoxia. This result suggests that
hypoxia-induced increase in DH IC-2 abundance is probably due to an
accumulation of the protein rather than translational effect on the
mRNA sequence. Under hypoxia, the overall protein synthesis is
known to be slowed down following a limitation in ATP supply [43].
However, some mRNA (like VEGF) are still translated due to the
presence of an IRES (internal ribosome entry site) sequence located in
the 5′ untranslated region of the mRNA [44]. In silico analyses did not
show such sequences in the DH IC-2 mRNA, leading to the conclusion
that hypoxia-induced DH IC-2 overexpression is probably a conse-
quence of the stabilization of this protein.
As post-translational modiﬁcations may increase the half-life of
proteins, we next checked if DH IC-2 was altered by hypoxia. The
results presented here clearly show that this protein is speciﬁcally
modiﬁed under this condition. The shift observed by 2D-blot to a less
acidic form of DH IC-2 suggests a loss of negative charges or a gain of
positive ones. Different in silico analysis tools were used in order to
deﬁne the potential modiﬁcation involved in the DH IC-2 shift
observed under hypoxia (data not shown). The NetPhos analysis
pointed out putative phosphorylation sites and the immunoprecipi-
tation studies showed that DH IC-2 is phosphorylated under normoxia
and become de-phosphorylated under prolonged hypoxia (16 h).
Calphostin C, a pan-inhibitor of PKC, also inhibited DH IC-2
phosphorylation while a decrease in PKC activity was observed after
a prolonged incubation under hypoxia. We thus suggest that it is
through PKC inhibition that hypoxia leads to the de-phosphorylation
of DH IC-2 that we observed. HepG2 cells contain four PKC isoforms
(α, δ, ɛ and ζ) [45]. Calphostin C inhibits all of them; further work is
thus required to identify the actual isoenzyme responsible for DH IC-2
phosphorylation under normoxia. Several PCK isoenzymes have been
found to be activated by short period of hypoxia in several cell types
[46–48]. We postulate that prolonged hypoxia may lead to PKC
deactivation through protein degradation as prolonged stimulation
with PMA does [49], thus resulting in a decreased PKC activity. This
hypothesis needs to be conﬁrmed.
As proteasome 26 s is one of the major systems involved in
protein turn over [35], we investigated if it could be implicated in
DH IC-2 degradation. Proteasome activity was inhibited under
normoxia by MG132 without any impact on DH IC-2 protein level
suggesting that another pathway is in charge of its maintenance.
Further work is needed to elucidate the mechanism involved in DH
IC-2 degradation.
As we identiﬁed different cytoskeleton proteins, and as cytoplas-
mic dynein is involved in a variety of mechanisms like intracellular
transport, mitosis, cell polarization and directed cell movement [28],
which could be of particular interest in cancer progression, we
decided to evaluate the implication of dynein on cancer cell migration.
First, hypoxia was shown to enhance in vitro HepG2 cells mobility,
which is in accordance with different literature data generated in vitro
or in vivo [9,37]. Second, invalidation of DH IC-2 by siRNA increased
HepG2 cell migration, to the same extent than hypoxia. The overall
abundance of DH IC-2 is increased under hypoxia but the protein is no
longer phosphorylated. In these conditions, HepG2 migration is
increased. Two hypotheses can thus be put forward to explain these
observations: (i) it is the abundance of DH IC-2 that regulates
migration or (ii) it is the phosphorylation state of DH IC-2 that
regulates migration. Since decreased DH IC-2 expression by siRNA
enhanced cell migration, it is not its abundance that regulates
migration. Indeed, if it would have been the case, an inhibition should
Fig. 10. Effect of pan-PKC inhibition on HepG2migration. HepG2 cells were plated in Boyden-like chambers for 24 h and incubated under normoxia, normoxia+ calphostin C at 2 μM
or hypoxia. (A) Cells that have migrated were stained with crystal violet. (B) The actual number of cells that have migrated has been counted on three ﬁelds for each membrane of
each experiment. The results are expressed in induction fold for three independent experiments, as means±SD (n=3). ⁎⁎ or ⁎⁎⁎, pb0.01 or pb0.001 vs. normoxia.
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form of DH IC-2 that inhibits migration, while the unphosphorylatedFig. 11. Effect of DH IC-2 invalidation on HepG2 proliferation. HepG2 cells were
transfected with DH IC-2-directed siRNA for 24 h (NT=non-transfected, DF=
Dharmafect 1 transfection agent, Scr=non-targeting siRNA, DH IC-2=DH IC-2 siRNA
smartpool). HepG2 cells were re-plated 24 h post-transfection and, 1 day later,
incubated 24 h under normoxia and hypoxia. Optical density was measured at 570 nm.
Results are presented as means±SD (n=4).one favors migration: hypoxia, by inhibiting PKC activity and, hence,
DH IC-2 phosphorylation would thus enhance cell migration. We have
conﬁrmed this hypothesis using calphostin C, a speciﬁc PKC inhibitor:
under normoxia, PKC inhibition also resulted in an enhanced
migration. In conclusion, hypoxia enhances migration by inhibiting
DH IC-2 phosphorylation. This effect was purely due to motility since
there was no effect on cell proliferation. This last result is surprising,
as dynein is known to play a role in spindle assembly [50]. However,
as DH IC-2 is a multi-subunit complex protein, it is possible that DH
IC-2 is not necessary for spindle assembly or could be replaced by a
redundant protein.
Taken together, these results suggest that DH IC-2 is modiﬁed
under hypoxia. This modiﬁcation could disrupt dynein complex and,
in turn, lead to the accumulation of DH IC-2 into the cytoplasm. As
intermediate chains are crucial for dynein assembly and to monitor
partner interactions [51,52], we hypothesized that the exclusion of
this modiﬁed form of DH IC-2 may change the set of the dynein
interacting proteins or may disturb normal dynein functions,
enhancing cell migration. These results are important for understand-
ing cancer development as they highlight a new HIF-1 independent
mechanism involved in metastasis.
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